Bausch Health Companies
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devi...
Latest News
4 days ago · zacks.com
Here's Why Bausch Health (BHC) is a Strong Momentum StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
11 days ago · prnewswire.com
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).
13 days ago · zacks.com
BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan RisksBausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.
14 days ago · zacks.com
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.
19 days ago · zacks.com
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesBausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
19 days ago · seekingalpha.com
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call TranscriptBausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 2026 Earnings Conference Call. As a reminder, this conference is being recorded.
19 days ago · zacks.com
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
19 days ago · zacks.com
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue EstimatesBausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.
19 days ago · marketbeat.com
What Bausch Health Cos (BHC) Said on Its Q3 Earnings CallBausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.
19 days ago · prnewswire.com
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 pursuant to which it will redeem approximately $643 million of aggregate principal amount of its outstanding 8.500% Senior Notes due 2027, CUSIP Nos. 91911XAW4 and U9098VAP7 (the "Notes"), using cash on hand.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BHC